Artificial Intelligence: CARES Act Funds Flow to the Pentagon for COVID-19 Vaccines; Lt. Gen. Jack Shanahan Retires at JAIC
The Department of Defense has added its AI muscle to the fight against COVID-19.
In April the Department of Defense (DoD) announced plans to use AI and machine learning against COVID-19 and other future virus attacks. The DoD has now unveiled a spending plan to revamp its AI capabilities to “rapidly screen, prioritize, and test Food and Drug Administration approved therapeutics for new COVID-19 drug candidates and human test trials for vaccines and antibody-based treatments.” (HEALTH IT ANALYTICS)
The DoD received a total of $10.5 billion in emergency funding within Division B — Emergency Appropriations for Coronavirus Health Response and Agency Operations of the CARES Act. The DoD was authorized by Congress to adjust its appropriations in line with the rapidly evolving nature of the Coronavirus Disease 2019 (COVID-19) response.
Accordingly, DoD is proposing to fund its AI/COVID-19 plans out of an amount of $3.8 billion for the Defense Health Program under the CARES Act. The DoD will use the funds to prepare for, prevent, and respond to the COVID-19 pandemic.
The funds would go into the Pentagon’s research and development accounts.
“DoD continues to rapidly adapt its response to the COVID-19 pandemic to protect the force and ensure the continuation of DoD missions,” the report stated. “Without this funding, such rapid AI-enabled screening capabilities cannot be established in time to respond to the current crisis.”
The amounts appropriated are as follows:
- $304K – To apply artificial intelligence (AI)-based models to rapidly screen, prioritize and test Food and Drug Administration (FDA)-approved therapeutics for new COVID-19 drug candidates.
- $5 million – to identify Food and Drug Administration (FDA)-approved drugs that could be repurposed as effective treatments for COVID-19.
- $52 million – to prevent, diagnose, and treat COVID-19.
- $619K – to apply AI to rapidly screen, prioritize and test FDA-approved therapeutics for new COVID-19 drug candidates.
- $2 million – to rapidly develop and field a potential capability to detect airborne Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Enable persistent, broad-scale environmental screening for contagions. Example airports, mass transportation hubs, and public areas where community transmission control is critical.
- $53.08 million – to test ultra-sensitive methods for diagnosing COVID-19. Develop U.S. sourced production capabilities for chemical precursors needed to produce pharmaceuticals critical to SARS-CoV-2/COVID-19. Assess the efficacy of the Food and Drug Administration (FDA)-approved therapeutic drug candidates for the treatment of COVID-19.
The DoD has formed a team at the Pentagon as well as a crisis management team at the Joint Staff’s facility in Suffolk, Virginia.
Lt Gen Jack Shanahan, the first Director of the Pentagon’s Joint Artificial Intelligence Centre (JAIC) has laid down the reins on June 1.
He handed over charge to chief technology officer, Nand Mulchandani.
Mulchandani will be acting director until a permanent three-star general or flag officer is confirmed. He has over 26 years of experience at Silicon Valley – doing this for a living at software companies.
Related Story: Lt. Gen. Jack Shanahan, Pentagon’s AI Chief to Retire
Latest Alternative Investment News
Funds and accounts advised by T. Rowe Price Associates, Inc. led an investment round worth $2.5 billion in electric vehicle maker Rivian. Participants in this investment round include Soros Fund…
PE Partnership Terms – Best Practices Callan, an institutional investment consulting firm, released its Private Equity Fees and Terms Study to serve as a reference for institutional investors. This study…
Clear, a blockchain startup founded in 2018, specializes in removing complex frictions in B2B trade. One such pain point is the contractual settlement and reconciliation for roaming agreements between telecom…
Alternative Investment: Vanguard Launches Its First ESG-focused Fixed Income Product For U.S. Investors
Vanguard filed a preliminary prospectus for a corporate bond ETF that will offer U.S. investors investment-grade corporate bonds with additional exposure to environmental, social, and governance (ESG) criteria. Vanguard has…